ADA and severe combined immunodeficiency: Gene modifications of HSCs show promise to treat diseases like ADA SCID (adenosine deaminase severe combined immunodeficiency disease) and gene-modified MSCs are just entering the first clinical trials for indications such as advanced adenocarcinoma.